臨床薬理の進歩 No.42

33/228

1） 国立がん研究センターがん情報サービス「がん登録・統計」地域がん登録2013年全国推計値，2017年2） Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001; 98(11): 6396-401.3） Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol 2019; 49(3): 201-9.4） Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.Clin Cance Res 2005; 11(21): 7886-90.5） Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, et al. Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncolytics 2020; 17: 205-15.6） Yamada T, Tateishi R, Iwai M, Koike K, Todo T. Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncolytics 2020; 18: 535-45.7） 田中 実, 藤堂 具紀. G47Δを用いた悪性グリオーマのウイルス療法. 脳外誌 2016; 25(12): 973-8.8） Nakatake R, Kaibori M, Nakamura Y, Tanaka Y, Matsushima H, Okumura T, et al. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci 2018; 109(3): 600-10.9） Matsushima H, Kaibori M, Hatta M, Ishizaki M, Nakatake R, Okumura T, et al. Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models. Oncotarget 2019; 10(67): 7132-41.10）Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006; 12(2): 643-52.11）Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 2016; 107(10): 1373-9.文　　　献　19